Explore
Validate
LearnHPA041275
antibody from Atlas Antibodies
Targeting: SYNCRIP
dJ3J17.2, GRY-RBP, hnRNP-Q, HNRNPQ, HNRPQ1, NSAP1
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA041275 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA041275, RRID:AB_2677389
- Product name
- Anti-SYNCRIP
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human SYNCRIP, Gene description: synaptotagmin binding, cytoplasmic RNA interacting protein, Alternative Gene Names: dJ3J17.2, GRY-RBP, hnRNP-Q, HNRNPQ, HNRPQ1, NSAP1, Validated applications: ICC, IHC, WB, Uniprot ID: O60506, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references hnRNP Q/SYNCRIP interacts with LIN28B and modulates the LIN28B/let-7 axis in human hepatoma cells
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
Physiological tissue-specific and age-related reduction of mouse TDP-43 levels is regulated by epigenetic modifications
Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset PD patient fibroblasts
Caputi M, Chang J, Lin T, Jhang X, Chan S
PLOS ONE 2024;19(7):e0304947
PLOS ONE 2024;19(7):e0304947
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
Li X, Wang Y, Deng S, Zhu G, Wang C, Johnson N, Zhang Z, Tirado C, Xu Y, Metang L, Gonzalez J, Mukherji A, Ye J, Yang Y, Peng W, Tang Y, Hofstad M, Xie Z, Yoon H, Chen L, Liu X, Chen S, Zhu H, Strand D, Liang H, Raj G, He H, Mendell J, Li B, Wang T, Mu P
Cancer Cell 2023;41(8):1427-1449.e12
Cancer Cell 2023;41(8):1427-1449.e12
Physiological tissue-specific and age-related reduction of mouse TDP-43 levels is regulated by epigenetic modifications
Pacetti M, De Conti L, Marasco L, Romano M, Rashid M, Nubiè M, Baralle F, Baralle M
Disease Models & Mechanisms 2022;15(4)
Disease Models & Mechanisms 2022;15(4)
Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset PD patient fibroblasts
Buratti E, Peruzzo P, Braga L, Zanin I, Stuani C, Goina E, Romano M, Giacca M, Dardis A
Molecular Therapy - Methods & Clinical Development 2021;20
Molecular Therapy - Methods & Clinical Development 2021;20
No comments: Submit comment
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent staining of human cell line U-2 OS shows localization to nucleoplasm & cytosol.
- Sample type
- Human
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Enhanced method
- Orthogonal validation
- Main image
- Experimental details
- Immunohistochemistry analysis in human thyroid gland and pancreas tissues using Anti-SYNCRIP antibody. Corresponding SYNCRIP RNA-seq data are presented for the same tissues.
- Sample type
- Human
- Protocol
- Protocol
